The European Union's Joint Clinical Assessment (JCA) heralds a dramatic change in the landscape of health technology market access, starting in 2025. While this new framework promises greater EU-wide harmonization, its practical implications are still uncertain. One certainty, however, is that the JCA’s requirement to benchmark every proposed therapy against a large number of PICOs (Population, Intervention, Comparator, Outcome) will lead to a dramatic increase in workload for healthcare developers. Without technology, these deadlines are impossible to meet. It is here where AI will play a pivotal role in bringing new drugs to patients faster.
This talk will shed light on the emerging JCA regime, explain why healthcare innovators must tackle market access early on, and showcase a cutting-edge generative AI application for the automatic interpretation of clinical results.
Speakers
Heike Kielhorn-Schönermark, Chief Operating and Transformation Officer @ Kintiga
Prof. Matthias P. Schönermark, Chief Strategy Officer @ Kintiga
